Abstract
La mielofibrosis (MF) se observa en el 10-20% de los pacientes con síndrome mielodisplásico (SMD). Su presencia es reconocida como un hallazgo histológico adverso asociado a curso agresivo, fallo medular temprano, sobrevida acortada y evolución leucémica. El objetivo fue examinar la influencia de la MF (MF ≥1) en la sobrevida global (SG) y su asociación con variables clínicas e histopatológicas. Se identificaron 468 pacientes con SMD incluidos en el Registro Argentino de SMD de 2007 a 2017. La mediana de SG del subgrupo MF ≥1 fue de 20,1 meses (IC 95%: 10,1-30,0) versus 67,6 meses (IC 95% 45,1-90,3) del subgrupo MF-0 (p<0,001). Los resultados destacan la presencia de MF ≥1 como un factor pronóstico adverso para la supervivencia en SMD, asociado con hiperferritinemia y alteración de la localización de la progenie eritroide en la médula ósea.
Introduction
Myelodysplastic Syndromes (MDS) are a complex group of blood cancers where the bone marrow fails to produce enough healthy, functioning blood cells. While clinicians rely on scoring systems like the IPSS-R to predict outcomes, these models often overlook the physical state of the bone marrow microenvironment. Bone marrow fibrosis (MF)—the buildup of scar-like reticulin fibers—occurs in approximately 10–20% of MDS patients. This study, utilizing data from the Argentinian Registry of MDS, investigates whether this scarring is a standalone risk factor or merely a byproduct of other complications, clarifying its prognostic weight and relationship with clinical markers like iron levels.
Methods
The researchers conducted a retrospective multicenter study using data from the Registro Argentino de SMD (Argentinian Registry of MDS). From an initial pool of 706 patients, 468 were selected based on the availability of bone marrow biopsy data recorded between 2007 and 2017.
Fibrosis was graded from 0 to 3 based on the European Myelodysplastic Network (EUMNET) criteria, with "MF ≥ 1" serving as the threshold for the presence of fibrosis. The study utilized Kaplan-Meier curves to estimate overall survival (OS) and Cox regression analysis to determine if fibrosis acted as an independent predictor when adjusted for variables such as age, hemoglobin levels, platelet counts, and chromosomal abnormalities.
Key Results and Survival Impact
The study revealed a massive survival gap based on the presence of marrow scarring. The presence of any grade of fibrosis (MF ≥ 1) was associated with a median overall survival of just 20.1 months, compared to 67.6 months for patients without fibrosis (MF-0).
Independent Predictors of Reduced Survival
Multivariate modeling confirmed that fibrosis is an independent "red flag." Even when accounting for high blast counts or high-risk genetics, MF ≥ 1 carried a Hazard Ratio (HR) of 1.46, indicating a 46% higher risk of death. Other independent predictors identified included:
- Bone marrow blasts > 5%: HR 2.94
- Charlson Comorbidity Index > 3: HR 2.17
- Poor Performance Status (> 2): HR 2.07
- Platelet count < 100,000/μL: HR 1.94
- Adverse Karyotypes: HR 1.86
- Hemoglobin < 10 g/dL: HR 1.64
The Iron and Structural Connection
One of the most striking findings was the association between fibrosis and iron overload. Patients with ferritin levels >1000 ug/L had an Odds Ratio (OR) of 3.41 for the presence of fibrosis. This suggests that iron overload—often exacerbated by frequent blood transfusions—may trigger a pro-inflammatory cycle that encourages marrow scarring.
Furthermore, fibrosis was linked to "atypical erythroid localization" (OR 2.65). This indicates that the physical scarring of the marrow niche disrupts the "geography" of blood production, physically displacing red blood cell precursors and contributing to marrow failure.
Conclusion
The presence of bone marrow fibrosis (MF ≥ 1) is a critical adverse prognostic factor in MDS, significantly shortening survival regardless of other clinical markers. The strong correlation with hyperferritinemia suggests that managing iron levels may be vital in addressing the pro-inflammatory environment of the marrow. Ultimately, the researchers argue that checking for fibrosis via biopsy should be a standard part of the diagnostic workup to better tailor treatment intensity for high-risk patients.
Summary updated